Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Relay Therapeutics Inc shares valued at $1,840 were sold by Rahmer Peter on Sep 27 ’24. At $7.51 per share, Rahmer Peter sold 245 shares. The insider’s holdings dropped to 391,684 shares worth approximately $2.54 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Catinazzo Thomas sold 6,457 shares, netting a total of over 48,184 in proceeds. Following the sale of shares at $7.46 each, the insider now holds 313,193 shares.
Before that, Bergstrom Donald A had sold 648 shares from its account. In a trade valued at $4,866, the President, R&D traded Relay Therapeutics Inc shares for $7.51 each. Upon closing the transaction, the insider’s holdings decreased to 648 shares, worth approximately $3.4 million.
As published in a research note from Jefferies on September 10, 2024, Relay Therapeutics Inc [RLAY] has been rated up from a Hold to a Buy and the price target has been revised to $16 from $10.60. As of September 10, 2024, Oppenheimer has decreased its “an Outperform” rating to a “Perform” for RLAY. Earlier on May 10, 2024, Barclays upgraded its rating. Their new recommendation was “an Overweight” for RLAY stock which previously was a “an Equal weight”.
Analyzing RLAY Stock Performance
During the last five days, there has been a drop of approximately -8.07%. Over the course of the year, Relay Therapeutics Inc shares have dropped approximately -41.05%. Shares of the company reached a 52-week high of $12.14 on 01/08/24 and a 52-week low of $5.70 on 04/24/24. A 50-day SMA is recorded $7.35, while a 200-day SMA reached $8.13. Nevertheless, trading volume fell to 1.98 million shares from 1.69 million shares the previous day.
Support And Resistance Levels for Relay Therapeutics Inc (RLAY)
According to the 24-hour chart, there is a support level at 6.31, which, if violated, would cause prices to drop to 6.13. In the upper region, resistance lies at 6.63. The next price resistance is at 6.77. RSI (Relative Strength Index) is 40.80 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.65, which suggests the price will decrease in the coming days. Percent R is at 89.24%, indicating bearish price movement. Stochastics %K at buying indicates that the stock is to be held.
